BALAXI PHARMA LTD (BALAXI) financials

BALAXI PHARMA LTD (BALAXI) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.[1]

Market Cap: ₹122Cr.
Current Price: ₹22.1
Stock P/E: 33.0
ROE: 3.95%
ROCE: 6.07%
Book Value: ₹24.1
Dividend Yield: 0.00%
52W High / Low: ₹43.8/15.2

In Jun 2026, BALAXI PHARMA LTD (BALAXI) reported sales ₹15.58 Cr and net profit ₹-1.25 Cr.

Annual TTM: sales ₹79.72 Cr, net profit ₹3.70 Cr.

Shareholding: Promoters 65.99% (Sep 2026), FIIs 0.00% (Sep 2026), DIIs 2.56% (Sep 2026), Public 31.45% (Sep 2026), No. of Shareholders 14,474% (Sep 2026).

BALAXI quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	21.16	11.16	9.65	16.71	19.31	24.59	20.24	15.58
Expenses	19.68	11.06	10.31	16.17	18.53	23.21	22.17	16.57
Operating Profit	1.48	0.10	-0.66	0.54	0.78	1.38	-1.93	-0.99
OPM %	6.99%	0.90%	-6.84%	3.23%	4.04%	5.61%	-9.54%	-6.35%
Other Income	1.29	2.92	0.32	0.46	4.21	1.62	3.37	0.92
Interest	0.45	0.57	0.69	0.63	0.62	0.73	0.71	0.45
Depreciation	0.12	0.11	0.11	0.11	0.12	0.15	0.31	0.59
Profit before tax	2.20	2.34	-1.14	0.26	4.25	2.12	0.42	-1.11
Tax %	24.55%	25.21%	3.51%	23.08%	22.82%	27.83%	61.90%	12.61%
Net Profit	1.66	1.74	-1.18	0.19	3.26	1.53	0.16	-1.25
EPS in Rs	0.30	0.32	-0.21	0.03	0.59	0.28	0.03	-0.23
Raw PDF	—	—	—	—	—	—	—	—

BALAXI profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	45.63	86.87	101.29	108.14	70.20	60.99	80.85	79.72
Expenses	36.98	67.85	83.99	91.26	64.78	58.38	79.86	80.48
Operating Profit	8.65	19.02	17.30	16.88	5.42	2.61	0.99	-0.76
OPM %	18.96%	21.89%	17.08%	15.61%	7.72%	4.28%	1.22%	-0.95%
Other Income	0.59	1.81	2.75	6.60	2.33	5.37	9.67	10.12
Interest	0.05	0.15	0.10	0.51	1.66	2.24	2.93	2.51
Depreciation	0.01	0.09	0.25	0.52	0.51	0.46	0.70	1.17
Profit before tax	9.18	20.59	19.70	22.45	5.58	5.28	7.03	5.68
Tax %	29.30%	26.52%	25.53%	27.75%	34.59%	31.82%	26.74%	—
Net Profit	6.50	15.13	14.67	16.22	3.65	3.60	5.15	3.70
EPS in Rs	1.30	3.03	2.93	3.19	0.67	0.65	0.93	0.67
Dividend Payout %	0.00%	0.00%	3.41%	0.00%	0.00%	0.00%	0.00%	—

BALAXI balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	3.04	10.00	10.00	10.00	10.18	10.90	11.04	11.04
Reserves	0.48	18.11	33.25	47.91	81.93	110.65	116.81	121.96
Borrowings	0.00	0.00	3.51	1.93	12.44	15.70	32.18	35.29
Other Liabilities	2.59	9.79	22.16	22.07	25.17	17.12	14.41	23.88
Total Liabilities	6.11	37.90	68.92	81.91	129.72	154.37	174.44	192.17
Fixed Assets	0.01	0.19	0.69	2.20	7.89	7.10	6.67	41.37
CWIP	0.00	0.00	0.00	0.57	2.83	2.31	22.07	0.00
Investments	0.00	0.10	19.54	19.61	19.54	19.88	25.07	79.51
Other Assets	6.10	37.61	48.69	59.53	99.46	125.08	120.63	71.29
Total Assets	6.11	37.90	68.92	81.91	129.72	154.37	174.44	192.17

BALAXI cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-1.51	-14.37	13.46	8.89	-7.07	-1.83	-7.60	43.87
Cash from Investing Activity	-0.01	-0.28	-20.03	-6.87	-2.29	0.46	-24.98	-67.77
Cash from Financing Activity	0.00	18.10	3.49	-1.64	26.39	27.55	17.21	0.54
Net Cash Flow	-1.51	3.44	-3.08	0.38	17.04	26.19	-15.37	-23.35
Free Cash Flow	-1.52	-14.55	12.87	6.56	-9.44	-1.02	-27.39	30.54
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	-97%	-158%	84%	84%	-10%	60%	-228%	4,603%

BALAXI shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	65.99%	65.99%	65.99%	65.99%	65.99%	65.99%	65.99%	65.99%
FIIs	16.48%	16.02%	8.87%	3.50%	1.74%	0.00%	0.00%	0.00%
DIIs	0.02%	0.02%	0.02%	0.02%	0.02%	2.56%	2.56%	2.56%
Public	17.50%	17.96%	25.12%	30.49%	32.24%	31.45%	31.45%	31.45%
No. of Shareholders	8,529	9,994	13,737	14,620	15,085	15,176	14,682	14,474

BALAXI key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	146.81	249.73	202.23	187.78	264.25	399.11	538.13	289.83
Inventory Days	—	9.23	0.12	0.00	6.62	5.43	0.00	0.00
Days Payable	—	81.27	95.96	—	76.73	80.38	—	—
Cash Conversion Cycle	146.81	177.69	106.38	187.78	194.14	324.16	538.13	289.83
Working Capital Days	82.12	186.70	94.62	105.47	156.31	253.73	282.17	43.07
ROCE %	96.25%	58.36%	55.40%	37.15%	27.93%	6.05%	5.06%	6.07%

BALAXIUpdated 18 Oct 2026, 7:16

Balaxi Pharma Ltd

BALAXIUpdated 18 Oct 2026, 7:16

Market Cap

₹122Cr.

Current Price

₹22.1

High / Low

₹43.8/15.2

Stock P/E

33.0

ROE3.95%

ROCE6.07%

Book Value₹24.1

Face Value₹2.00

Dividend Yield0.00%

About

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	25.04	0.26	21.27	0.13	0.13	3.51	27.35	2.55	0.5
Sep 2023	16.55	0.36	15.64	1.15	0.13	1.57	24.84	1.18	0.23
Dec 2023	12.7	0.41	12.42	1.03	0.13	0.77	36.36	0.49	0.1
Mar 2024	15.9	0.51	15.7	0.16	0.12	-0.27	114.81	-0.58	-0.11
Jun 2024	19.03	0.35	17.53	0.85	0.12	1.88	27.13	1.38	0.25
Sep 2024	21.16	0.45	19.68	1.29	0.12	2.2	24.55	1.66	0.3
Dec 2024	11.16	0.57	11.06	2.92	0.11	2.34	25.21	1.74	0.32
Mar 2025	9.65	0.69	10.31	0.32	0.11	-1.14	3.51	-1.18	-0.21
Jun 2025	16.71	0.63	16.17	0.46	0.11	0.26	23.08	0.19	0.03
Sep 2025	19.31	0.62	18.53	4.21	0.12	4.25	22.82	3.26	0.59
Dec 2025	24.59	0.73	23.21	1.62	0.15	2.12	27.83	1.53	0.28
Mar 2026	20.24	0.71	22.17	3.37	0.31	0.42	61.9	0.16	0.03
Jun 2026	15.58	0.45	16.57	0.92	0.59	-1.11	12.61	-1.25	-0.23

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	0.12	0.01	0.08	0.12	0	0.15	26.67	0.1	0.07
Mar 2016	0.05	0.05	0.11	0	0	-0.11	-36.36	-0.08	-0.05
Mar 2017	0	0.04	0.13	0	0	-0.17	0	-0.17	-0.11
Mar 2018	0	0	0.77	0	0	-0.77	0	-0.77	-0.51
Mar 2019	13.6	0	12.05	0.89	0	2.44	19.26	1.97	1.3
Mar 2020	45.63	0.05	36.98	0.59	0.01	9.18	29.3	6.5	1.3
Mar 2021	86.87	0.15	67.85	1.81	0.09	20.59	26.52	15.13	3.03
Mar 2022	101.29	0.1	83.99	2.75	0.25	19.7	25.53	14.67	2.93
Mar 2023	108.14	0.51	91.26	6.6	0.52	22.45	27.75	16.22	3.19
Mar 2024	70.2	1.66	64.78	2.33	0.51	5.58	34.59	3.65	0.67
Mar 2025	60.99	2.24	58.38	5.37	0.46	5.28	31.82	3.6	0.65
Mar 2026	80.85	2.93	79.86	9.67	0.7	7.03	26.74	5.15	0.93
TTM	79.72	2.51	80.48	10.12	1.17	5.68	—	3.7	0.67

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	65.99%
DIIs	2.56%
Public	31.45%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	71.22%	18.57%	0.03%	10.18%
Mar 2024	66.86%	17.21%	0.02%	15.91%
Jun 2024	65.99%	16.88%	0.02%	17.11%
Sep 2024	65.99%	16.48%	0.02%	17.5%
Dec 2024	65.99%	16.48%	0.02%	17.5%
Mar 2025	65.99%	16.02%	0.02%	17.96%
Jun 2025	65.99%	8.87%	0.02%	25.12%
Sep 2025	65.99%	3.5%	0.02%	30.49%
Dec 2025	65.99%	1.74%	0.02%	32.24%
Mar 2026	65.99%	0%	2.56%	31.45%
Jun 2026	65.99%	0%	2.56%	31.45%
Sep 2026	65.99%	0%	2.56%	31.45%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	3.04	0.18	0	0.46	3.68	0	0	3.42	0.26	3.68
Mar 2016	3.04	0.11	0.2	0.22	3.57	0	0	3.29	0.28	3.57
Mar 2017	3.04	-0.72	0	0.05	2.37	0	0	0	2.37	2.37
Mar 2018	3.04	-1.49	0	0.13	1.68	0.01	0	0	1.67	1.68
Mar 2019	3.04	0.48	0	2.59	6.11	0.01	0	0	6.1	6.11
Mar 2020	10	18.11	0	9.79	37.9	0.19	0	0.1	37.61	37.9
Mar 2021	10	33.25	3.51	22.16	68.92	0.69	0	19.54	48.69	68.92
Mar 2022	10	47.91	1.93	22.07	81.91	2.2	0.57	19.61	59.53	81.91
Mar 2023	10.18	81.93	12.44	25.17	129.72	7.89	2.83	19.54	99.46	129.72
Mar 2024	10.9	110.65	15.7	17.12	154.37	7.1	2.31	19.88	125.08	154.37
Mar 2025	11.04	116.81	32.18	14.41	174.44	6.67	22.07	25.07	120.63	174.44
Mar 2026	11.04	121.96	35.29	23.88	192.17	41.37	0	79.51	71.29	192.17

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	0.21	-3.11	2.38	-0.52
Mar 2016	-0.03	0.13	-0.11	-0.02
Mar 2017	-0.13	2.67	-0.24	2.3
Mar 2018	-0.68	-0.01	0	-0.69
Mar 2019	-1.51	-0.01	0	-1.51
Mar 2020	-14.37	-0.28	18.1	3.44
Mar 2021	13.46	-20.03	3.49	-3.08
Mar 2022	8.89	-6.87	-1.64	0.38
Mar 2023	-7.07	-2.29	26.39	17.04
Mar 2024	-1.83	0.46	27.55	26.19
Mar 2025	-7.6	-24.98	17.21	-15.37
Mar 2026	43.87	-67.77	0.54	-23.35

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	30.42	0.00	—	—	146.81	249.73	202.23	187.78	264.25	399.11	538.13	289.83
Inventory Days	—	—	—	—	—	9.23	0.12	0.00	6.62	5.43	0.00	0.00
Days Payable	—	—	—	—	—	81.27	95.96	—	76.73	80.38	—	—
Cash Conversion Cycle	30.42	0.00	—	—	146.81	177.69	106.38	187.78	194.14	324.16	538.13	289.83
Working Capital Days	-669.17	-1,387.00	—	—	82.12	186.70	94.62	105.47	156.31	253.73	282.17	43.07
ROCE %	7.66%	-1.83%	-4.59%	-39.79%	96.25%	58.36%	55.40%	37.15%	27.93%	6.05%	5.06%	6.07%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of BALAXI PHARMA LTD (BALAXI)?

The reported market capitalisation for BALAXI PHARMA LTD (BALAXI) is ₹122Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of BALAXI?

The current price shown for BALAXI PHARMA LTD (BALAXI) on Fincrux is ₹22.1 with a 52-week high/low of ₹43.8/15.2.

What is the P/E ratio of BALAXI PHARMA LTD (BALAXI)?

The stock P/E for BALAXI PHARMA LTD (BALAXI) is 33.0 on Fincrux, with ROE at 3.95% and ROCE at 6.07%.

What were BALAXI latest quarterly results?

For Jun 2026, BALAXI PHARMA LTD (BALAXI) reported sales ₹15.58 Cr and net profit ₹-1.25 Cr (figures in ₹ crore unless noted).

What are BALAXI annual sales and net profit?

For TTM, BALAXI PHARMA LTD (BALAXI) shows sales of ₹79.72 Cr and net profit of ₹3.70 Cr on the Fincrux profit & loss statement.

Who owns BALAXI PHARMA LTD (BALAXI)?

Latest shareholding for BALAXI PHARMA LTD (BALAXI) on Fincrux: Promoters 65.99% (Sep 2026), FIIs 0.00% (Sep 2026), DIIs 2.56% (Sep 2026), Public 31.45% (Sep 2026), No. of Shareholders 14,474% (Sep 2026).

Where can I find BALAXI PHARMA LTD (BALAXI) financials?

BALAXI PHARMA LTD (BALAXI) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show BALAXI balance sheet and cash flow?

Yes. The BALAXI PHARMA LTD (BALAXI) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 7:16